What question did this study set out to answer?

This research aimed to evaluate the cardiovascular benefits of GLP-1 receptor agonist use among adults with type 1 diabetes and obesity.

June 10, 2026Diabetes

1292-OR: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonist Use among Adults with Type 1 Diabetes and Overweight or Obesity: A Target Trial Emulation Using Real-World EHR Data

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial emulates cardiovascular effects of GLP-1RA in adults with type 1 diabetes, suggesting clinical benefits.

This research aimed to evaluate the cardiovascular benefits of GLP-1 receptor agonist use among adults with type 1 diabetes and obesity.
Emulated a target trial using electronic health records from the Epic COSMOS database.
Included adults with type 1 diabetes and BMI ≥27 kg/m² who initiated GLP-1RA from 2020 to 2024, compared with matched nonusers.
Analyzed major adverse cardiovascular events (MACE) using Cox proportional hazards models.
GLP-1RA users showed a 31% lower risk of MACE (HR 0.69, 95% CI 0.63-0.76; p<0.001).
Significant reductions in the risk of atrial fibrillation (AF) (HR 0.82, 95% CI 0.70-0.96) and heart failure (HF) (HR 0.83, 95% CI 0.74-0.94) were also observed.
No significant link was found between GLP-1RA use and peripheral vascular disease (HR 1.04, 95% CI 0.94-1.16).

Shao et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark